Overall, the genetic ablation of nociceptor neurons decreases the growth of B16F10 tumours by preventing CD8+ T cells from undergoing exhaustion, whereas exogenous administration of CGRP has the opposite effect. The gene discussed is CD8A; the disease is neoplasm.